How data from HER2CLIMB-05 and PATINA are influencing treatment decisions
— How data from HER2CLIMB-05 and PATINA are influencing treatment decisions
by Gregory Laub, Senior Director, Video, MedPage Today
June 16, 2026
• 2 min read
At the American Society of Clinical Oncology (ASCO) meeting, updated HER2CLIMB-05 findings on the addition of tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) added to a growing conversation about maintenance strategies in HER2-positive metastatic breast cancer.
Jame Abraham, MD, discusses how DESTINY-Breast11 may reshape care
ASCENT-04 analysis finds PFS2 advantage as an indicator of long-term clinical benefit
Experts discuss oral SERDs, novel targeted combinations, and sequencing
New trastuzumab deruxtecan indications cover neoadjuvant and adjuvant treatment
Experts discuss Prosigna-guided treatment decisions in high-risk early disease
CHICAGO — The addition of two agents to standard first-line treatment significantly improved PFS among patients with aggressive…
